These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

94 related items for PubMed ID: 16360331

  • 1. Pharmacologic characteristics of prulifloxacin.
    Matera MG.
    Pulm Pharmacol Ther; 2006; 19 Suppl 1():20-9. PubMed ID: 16360331
    [Abstract] [Full Text] [Related]

  • 2. Prulifloxacin.
    Keam SJ, Perry CM.
    Drugs; 2004; 64(19):2221-34; discussion 2235-6. PubMed ID: 15456336
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. [In vitro antibacterial activity of prulifloxacin, a new oral fluoroquinolone].
    Araake M, Hara T, Watabe H, Nishino T.
    Jpn J Antibiot; 2002 Dec; 55(6):778-90. PubMed ID: 12621732
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Prulifloxacin: clinical studies of a broad-spectrum quinolone agent.
    Giannarini G, Tascini C, Selli C.
    Future Microbiol; 2009 Feb; 4(1):13-24. PubMed ID: 19207096
    [Abstract] [Full Text] [Related]

  • 10. [In vitro activity of prulifloxacin, levofloxacin and ciprofloxacin against urinary pathogens].
    Noviello S, Ianniello F, Leone S, Esposito S.
    Infez Med; 2006 Mar; 14(1):24-8. PubMed ID: 17405239
    [Abstract] [Full Text] [Related]

  • 11. [In vitro antibacterial activity of prulifloxacin, a new oral quinolone, and comparative susceptibility rate at clinical breakpoint MIC].
    Inoue M, Kuga A, Kaieda S, Hosaka M, Kitasato H, Sato Y, Okamoto R, Eda T, Hoshino K, Seto I.
    Jpn J Antibiot; 2000 Sep; 53(9):593-608. PubMed ID: 11214999
    [Abstract] [Full Text] [Related]

  • 12. In vitro activity of prulifloxacin against Escherichia coli isolated from urinary tract infections and the biological cost of prulifloxacin resistance.
    Gualco L, Schito AM, Schito GC, Marchese A.
    Int J Antimicrob Agents; 2007 Jun; 29(6):679-87. PubMed ID: 17363225
    [Abstract] [Full Text] [Related]

  • 13. [In vitro short-term bactericidal activity and accumulation of NM394, the active metabolite of prulifloxacin, for Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa: comparison with ciprofloxacin, levofloxacin, and gatifloxacin].
    Shimizu M, Tabata M, Hara T, Araake M, Watabe H, Nishino T.
    Jpn J Antibiot; 2002 Dec; 55(6):791-9. PubMed ID: 12621733
    [Abstract] [Full Text] [Related]

  • 14. [Susceptibility surveillance of clinical isolates to fluoroquinolone antimicrobial agents from 2003 to 2008: post-marketing study of prulifloxacin].
    Kawai S, Yoshida A, Okazaki M, Tsujihara Y, Inuzuka K, Takeuchi K, Yamashita N, Onodera M, Hiraishi T, Ida T, Maebashi K.
    Jpn J Antibiot; 2010 Jun; 63(3):242-54. PubMed ID: 20976880
    [Abstract] [Full Text] [Related]

  • 15. Interpretive criteria for disk diffusion susceptibility testing of ulifloxacin, the active metabolite of prulifloxacin.
    Montanari MP, Ferrante L, Tili E, Cochetti I, Rossi V, Varaldo PE.
    J Chemother; 2005 Apr; 17(2):138-42. PubMed ID: 15920898
    [Abstract] [Full Text] [Related]

  • 16. Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
    Fritsche TR, Biedenbach DJ, Jones RN.
    Antimicrob Agents Chemother; 2009 Mar; 53(3):1221-4. PubMed ID: 19114678
    [Abstract] [Full Text] [Related]

  • 17. Antibacterial activity of NM394, the active form of prodrug NM441, a new quinolone.
    Yoshida T, Mitsuhashi S.
    Antimicrob Agents Chemother; 1993 Apr; 37(4):793-800. PubMed ID: 8388199
    [Abstract] [Full Text] [Related]

  • 18. [Clinical study of prulifloxacin on infectious enteritis. Japan Research Committee of Prulifloxacin, Research Group on Infectious Enteritis].
    Tomizawa I, Takizawa Y, Nitta Y, Tsunoda T, Fukuda H, Yamaguchi T, Masuda G, Negishi M, Ajisawa A, Murata M, Ohnishi K, Irimajiri S, Obana M, Sajima Y, Sagara H, Kato H, Hosoda S, Banba T, Sasaki M, Yoshikawa K, Nakagawa M, Ohkubo H, Kim Y, Akao M, Fukuyama M.
    Kansenshogaku Zasshi; 1996 Jul; 70(7):727-45. PubMed ID: 8797308
    [Abstract] [Full Text] [Related]

  • 19. Prulifloxacin versus ciprofloxacin in the treatment of adults with complicated urinary tract infections.
    Carmignani G, De Rose AF, Olivieri L, Salvatori E, Rosignoli MT, Dionisio P.
    Urol Int; 2005 Jul; 74(4):326-31. PubMed ID: 15897698
    [Abstract] [Full Text] [Related]

  • 20. Penetration of orally administered prulifloxacin into human lung tissue.
    Concia E, Allegranzi B, Ciottoli GB, Orticelli G, Marchetti M, Dionisio P.
    Clin Pharmacokinet; 2005 Jul; 44(12):1287-94. PubMed ID: 16372826
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.